We have pulled together our broad network of global expertise in the life sciences space to bring you this Genomics Series. The articles will explore the intersection between genomics and law, offering insights into the challenges that face businesses operating in, or interfacing with, the genomics field, as well as the challenges facing legislators, regulators, and legal practitioners as they navigate the rapid advancements in gene-editing and other genomic technologies. Our goal is to highlight not only the revolutionary scientific potential, but also the crucial commercial, legal and ethical considerations that must guide and govern the future of genomics.
Should you have any queries, please reach out to the relevant DLA Piper contact, or else you can contact Freya Rose.
Loading...